Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Raymond C. Stevens
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 281
- Beta
- -1.52
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 10.72
Financials
Net Income
$-106.16MEBITDA
$-105.37MFree Cash Flow
$-120.07MEPS (diluted)
$-1.47Shares Outstanding (diluted)
72.65M+98.6%Operating Expenses
$118.63MCash & Debt
$1.34BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-141.20M | $-2.40 |
| 2024 | $0.00 | $-122.53M | $-2.34 |
| 2023 | $0.00 | $-89.62M | $-2.43 |
| 2022 | $0.00 | $-51.32M | $-1.44 |
| 2021 | $0.00 | $-40.01M | $-1.20 |
| 2020 | $0.00 | $-15.90M | $-0.45 |
Valuation
GPCRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+13.79%Social Signal Score
Mentions (6)
- Newszacks.com·6d ago·Positive
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·39d ago·Neutral
Structure Therapeutics: The Amylin Data Changes The Math Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…ucture Therapeutics to Participate in Upcoming Healthcare Investor Conferences SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare Conference Date: Thursday, September 10Forma…
View source ↗ - Newsseekingalpha.com·51d ago·Neutral
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key catalys…
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.33 per share
Typical surprise -12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.49 vs $-0.39miss
- Thu, May 7$-0.35 vs $-0.39beat
- Thu, Feb 26$-0.49 vs $-0.35miss
- Thu, Nov 6$-0.37 vs $-0.36miss
- Wed, Aug 6$-0.36 vs $-0.28miss
- Thu, May 8$-0.27 vs $-0.24miss
Estimates and results for GPCR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GPCR officers and directors.
- Bought
- —
- Sold
- —
0 trades
35 trades
- Coll Crespo Blassold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Richard Carpersenate · DE · disclosed Nov 2, 2023 (29d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.